Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
761-780 of 1,694 trials

Metastatic Colorectal Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with metastatic colorectal cancer who have not responded to standard care. The study aims to see if this new drug can improve survival and response rates compared to existing treatments.

Metastatic Colorectal CancerEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology

COVID-19 Treatment: Nirmatrelvir/Ritonavir for Children

We are studying a new oral medication for children with COVID-19 who are at risk of severe illness. The trial will evaluate its safety, how well it works, and how it is tolerated in young patients.

COVID-19Efficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Localized Prostate Cancer: Darolutamide and Radiation Therapy

We are studying the effects of darolutamide with or without radiation therapy in patients with localized prostate cancer at high risk of relapse. The goal is to see if this combination improves survival and quality of life.

Localized Prostate Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: JAK Inhibitor Dose Tapering Study

We are exploring whether reducing the dose of JAK inhibitors helps maintain low disease activity in rheumatoid arthritis patients. This study will also look at the impact on pain, function, and overall quality of life.

Rheumatoid Arthritis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesRheumatology

Ibrutinib for Autoimmune Hemolytic Anemia in CLL Patients

We are studying whether ibrutinib can effectively treat autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia or similar conditions. The trial will also look at the safety and quality of life during treatment.

Chronic Lymphocytic Leukemia (CLL)>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Childhood Leukemia: Inotuzumab Ozogamicin vs. ALLR3

We are studying whether Inotuzumab Ozogamicin works better than standard treatment for children with high-risk first relapse B-cell leukemia. The trial focuses on safety and long-term effectiveness in young patients.

Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyPediatrics

Oligometastatic Colorectal Cancer: OPTIMISE Study

We are exploring whether a blood test can help decide the best treatment for patients with oligometastatic colorectal cancer. The study also looks at how this approach affects quality of life and treatment costs.

Colorectal Cancer with MetastasisEfficacy phase (II)No PlaceboStandard MedicinesOncology

Everolimus for Bone and Muscle Health in the Elderly

We are studying whether everolimus can help prevent bone loss and improve muscle function in older adults. This research aims to address age-related health challenges.

Healthy Elderly Participants3-6 monthsStandard MedicinesInternal MedicineOrthopedics and Traumatology

Colon Cancer: Personalized Treatment Strategy

We are exploring whether a blood-based genomic approach can improve outcomes for patients with operable Stage III and high-risk Stage II colon cancer compared to standard chemotherapy. This study also looks at side effects and quality of life.

Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOncology

Acetyl-L-Carnitine for ALS Treatment

We are studying whether acetyl-L-carnitine can help slow down the progression of ALS and improve quality of life. Participants will receive different doses to see which is most effective and safe.

Amyotrophic Lateral Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesNeurology

Multiple Myeloma: Mezigdomide vs. Pomalidomide

We are studying whether a new drug, mezigdomide, combined with bortezomib and dexamethasone, is more effective than pomalidomide with the same drugs for patients with relapsed or refractory multiple myeloma.

Relapsed or Refractory Multiple Myeloma≤3 monthsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Liver Cirrhosis: Stopping Proton-Pump Inhibitors

We are studying whether stopping proton-pump inhibitors helps or harms patients with liver cirrhosis compared to those who continue the medication. This trial looks at hospitalizations, infections, and overall health outcomes.

Liver Cirrhosis1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesGastroenterologyInternal Medicine

Antiplatelet Therapy Reduction in High Bleeding Risk Patients

We are studying whether lowering the dose of antiplatelet medication helps patients with acute coronary syndrome who have had stents placed, while reducing the risk of bleeding. The trial compares different medication regimens to find the best balance between safety and effectiveness.

Acute Coronary Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Non-Small Cell Lung Cancer: Osimertinib with Datopotamab Deruxtecan

We are studying the safety and effectiveness of combining osimertinib with datopotamab deruxtecan in patients with advanced non-small cell lung cancer that has an EGFR mutation. This trial aims to see if the combination works better than osimertinib alone.

Non-Squamous Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Lower Limb Trauma: Rivaroxaban vs. Heparin

We are studying whether Rivaroxaban is as effective as low-molecular weight heparin in preventing blood clots in patients with lower limb injuries. This trial is for those at high risk of complications while in a cast or brace.

Lower Limb Trauma Requiring Immobilization≤3 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyOrthopedics and Traumatology

Stroke Treatment: Thrombolysis for Patients on Factor Xa Inhibitors

We are studying whether intravenous thrombolysis can improve recovery in stroke patients who have recently taken Factor Xa inhibitors. This trial compares the effects of this treatment to standard care options.

Acute Ischemic Stroke>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Mantle Cell Lymphoma: Zanubrutinib with Rituximab

We are comparing a new treatment combining Zanubrutinib and Rituximab to standard therapy for patients with untreated mantle cell lymphoma who cannot have a stem cell transplant. The goal is to see which treatment works better and is safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Oocyte Cryopreservation: Random Start Ovarian Stimulation

We are comparing a new method of ovarian stimulation with a traditional approach for women planning to freeze their eggs. This study aims to determine if the new method is equally effective.

Prevention of Female Infertility≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesEndocrinologyGynecology and Obstetrics

Chemotherapy Dose Adjustment for DPD-Deficient Gastrointestinal Cancer Patients

We are studying how to safely adjust chemotherapy doses for patients with gastrointestinal cancers who lack a specific liver enzyme. This may help reduce severe side effects during treatment.

Gastrointestinal Cancer Patients Starting Chemotherapy>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Metastatic Pancreatic Cancer: Dostarlimab with mFOLFIRINOX

We are studying a new treatment combining Dostarlimab, vitamin D3, and standard chemotherapy for patients with untreated metastatic pancreatic cancer. The goal is to see if this combination can effectively fight the cancer and assess its safety.

Metastatic Pancreatic Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology